CSPHF - CStone EQRx in licensing pact for two immuno-oncology assets

CStone Pharmaceuticals (CSPHF) has agreed to out-license ex-Greater China rights for sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1), to EQRx.Under the terms of the agreement, CStone will receive an upfront payment of $150M and up to $1.15B in milestone payments for both drugs as well as separate tiered royalties.EQRx will obtain exclusive rights to lead global development and commercialization worldwide, excluding Mainland China, Taiwan, Hong Kong and Macau.CStone retains rights to CS1003 in Greater China, where it can continue to pursue development as a monotherapy or in combination.Sugemalimab is a PD-L1 antibody that is being developed for high-incidence cancer indications in China, including frontline non-small cell lung, gastric and esophageal cancers, among others. The FDA has recently granted Breakthrough Therapy Designation to this drug for adult relapsed or refractory extranodal natural killer/T-cell lymphoma, and orphan drug status for T-cell lymphoma.CS1003 is currently being studied for the treatment of advanced solid tumors, including a global registration trial in first-line hepatocellular carcinoma. The

For further details see:

CStone, EQRx in licensing pact for two immuno-oncology assets